Literature DB >> 11315572

Adjuvant post-operative chemotherapy in bitches with mammary cancer.

M Karayannopoulou1, E Kaldrymidou, T C Constantinidis, A Dessiris.   

Abstract

The survival time in a group of eight bitches with malignant mammary tumours given adjuvant post-operative chemotherapy was compared with survival in another group of eight bitches with mammary cancer which were treated by surgical excision alone. The same surgical procedure was used in both groups. All bitches had stage III disease according to the World Health Organization clinical staging system. Histologically, 10 of the bitches had complex carcinomas (carcinomatous mixed tumours), the remaining six bitches had carcinosarcomas. The chemotherapeutic protocol used was a combination of 5-fluorouracil (150 mg/m2 of body surface area) and cyclophosphamide (100 mg/m2) given on the same day, intravenously, every week for four consecutive weeks. Chemotherapy was started one week post-surgery. Selected haematological parameters (packed cell volume, white blood cell count, platelet count and differential white blood cell count) and serum biochemical parameters (alanine aminotransferase, alkaline phosphatase, blood urea nitrogen and creatinine) were measured before and during chemotherapy. Survival analysis indicated that the chemotherapeutic regimen had a positive influence on the disease-free interval and the survival time of the eight bitches (P < 0.05). Although leucocyte numbers were significantly decreased (P < 0.001) during chemotherapy, the mean leucocyte counts remained within normal limits. Temporary leukopenia was noted only in one bitch. Packed cell volume and alkaline phosphatase increased significantly (P < 0.05) but within normal limits. Creatinine was also increased significantly (P < 0.01) but the mean creatinine concentrations were within normal limits, although in half of the bitches the concentrations occasionally rose above normal.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11315572     DOI: 10.1046/j.1439-0442.2001.00336.x

Source DB:  PubMed          Journal:  J Vet Med A Physiol Pathol Clin Med        ISSN: 0931-184X


  14 in total

1.  A clinical protocol for treatment of canine mammary tumors using encapsulated, cytochrome P450 synthesizing cells activating cyclophosphamide: a phase I/II study.

Authors:  Stanislaw Winiarczyk; Zbigniew Gradski; Barbara Kosztolich; Cornelia Gabler; Gerhardt König; Matthias Renner; Robert M Saller; Heinrich Prosl; Brian Salmons; Walter H Günzburg; Johannes Hain
Journal:  J Mol Med (Berl)       Date:  2002-06-28       Impact factor: 4.599

2.  5-Fluorouracil may enrich cancer stem cells in canine mammary tumor cells in vitro.

Authors:  Bin Zhou; Yipeng Jin; Di Zhang; Degui Lin
Journal:  Oncol Lett       Date:  2018-03-15       Impact factor: 2.967

3.  Expression of vimentin filaments in canine malignant mammary gland tumors: A simulation of clinicopathological features of human breast cancer.

Authors:  Sanaz Rismanchi; Orly Yadegar; Samad Muhammadnejad; Saeid Amanpour; Masoud Taghizadeh-Jahed; Ahad Muhammadnejad
Journal:  Biomed Rep       Date:  2014-07-08

4.  Phase I/II clinical trial of encapsulated, cytochrome P450 expressing cells as local activators of cyclophosphamide to treat spontaneous canine tumours.

Authors:  Monika Michałowska; Stanislaw Winiarczyk; Łukasz Adaszek; Wojciech Łopuszyński; Zbigniew Grądzki; Brian Salmons; Walter H Günzburg
Journal:  PLoS One       Date:  2014-07-16       Impact factor: 3.240

5.  Antiproliferative Effects of Oxytocin and Desmopressin on Canine Mammary Cancer Cells.

Authors:  Micaela Andrea Benavente; Carolina Paula Bianchi; Fernanda Imperiale; Marcelo Alfredo Aba
Journal:  Front Vet Sci       Date:  2016-12-26

6.  Molecular iodine/doxorubicin neoadjuvant treatment impair invasive capacity and attenuate side effect in canine mammary cancer.

Authors:  Xóchitl Zambrano-Estrada; Brianda Landaverde-Quiroz; Andrés A Dueñas-Bocanegra; Marco A De Paz-Campos; Gerardo Hernández-Alberto; Benjamín Solorio-Perusquia; Manuel Trejo-Mandujano; Laura Pérez-Guerrero; Evangelina Delgado-González; Brenda Anguiano; Carmen Aceves
Journal:  BMC Vet Res       Date:  2018-03-12       Impact factor: 2.741

7.  Pharmacokinetics and tolerance of repeated oral administration of 5-fluorocytosine in healthy dogs.

Authors:  Jérémy Béguin; Matthias Kohlhauer; Eve Laloy; Frédérique Degorce; Baptiste Moreau; Éric Quéméneur; Philippe Erbs; Bernard Klonjkowski; Christelle Maurey
Journal:  BMC Vet Res       Date:  2021-06-21       Impact factor: 2.741

8.  Expression and role of PGP, BCRP, MRP1 and MRP3 in multidrug resistance of canine mammary cancer cells.

Authors:  Karol M Pawłowski; Joanna Mucha; Kinga Majchrzak; Tomasz Motyl; Magdalena Król
Journal:  BMC Vet Res       Date:  2013-06-17       Impact factor: 2.741

9.  Tumor slices as a model to evaluate doxorubicin in vitro treatment and expression of trios of genes PRSS11, MTSS1, CLPTM1 and PRSS11, MTSS1, SMYD2 in canine mammary gland cancer.

Authors:  Renata A Sobral; Suzana T Honda; Maria Lucia H Katayama; Helena Brentani; M Mitzi Brentani; Diogo F C Patrão; Maria Aparecida A K Folgueira
Journal:  Acta Vet Scand       Date:  2008-07-04       Impact factor: 1.695

10.  Diagnosis, classification and grading of canine mammary tumours as a model to study human breast cancer: an Clinico-Cytohistopathological study with environmental factors influencing public health and medicine.

Authors:  Radmehr Shafiee; Javad Javanbakht; Nahid Atyabi; Pegah Kheradmand; Danial Kheradmand; Alimohammad Bahrami; Hasti Daraei; Farshid Khadivar
Journal:  Cancer Cell Int       Date:  2013-08-09       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.